Caren van Roekel

147 Mode of progression after radioembolization in colorectal cancer patients TABLE 2. Univariable Firth’s logistic regression analysis for baseline characteristics and type of progression: OR (95%CI) PD GIHM (n=20) GEHM (n=37) NIHM (n=35) NEHM (n=57) GM (n=45) NM (n=63) Age in years 1.02 (0.97;1.07) 0.99 (0.02;9.75) 1.01 (0.97;1.06) 1.02 (0.98, 1.06) 1.00 (0.96;1.05) 1.01 (0.97;1.06) 1.01 (0.97;1.05) Chemotherapy* 0.88 (0.01;88.46) 0.74 (0.26;2.01) 0.87 (0.37;2.05) 0.37 (0.14;0.91) 0.63 (0.26;1.51) 0.57 (0.24;1.33) 0.48 (0.19;1.19) Type of microspheres **–Glass 1.11 (0.32;4.53) 0.71 (0.18;2.41) 2.53 (0.87;7.56) 1.71 (0.59;4.99) 1.5 (0.50;4.89) 1.79 (0.62;5.35) 1.94 (0.59-7.65) Type of microspheres - Holmium 0.67 (0.22;2.14) 0.57 (0.14;1.88) 1.75 (0.63;4.86) 0.85 (0.29;2.38) 0.90 (0.33;2.50) 1.19 (0.44;3.22) 0.81 (0.29-2.31) Extrahepatic metastases at baseline 7.8 (2.37;35.53) 2.39 (0.89;6.84) NA 1.83 (0.79;4.32) 3.06 (1.28;7.72) NA 2.86 (1.14;7.66) Primary tumor in situ 1.90 (0.30;37.11) 0.76 (0.08;3.96) 1.12 (0.24;4.88) 3.86 (0.87;22.5) 2.73 (0.54;27.1) 1.32 (0.30;6.21) 2.00 (0.39;19.9) WHO status*** 0.87 (0.32;2.46) 0.43 (0.10;1.43) 0.91 (0.35;2.33) 0.90 (0.33;2.33) 0.50 (0.19;1.31) 0.86 (0.34;2.19) 0.81 (0.30;2.27) KRAS status§ 3.38 (0.75;23.95) 1.88 (0.56;6.45) 2.75 (0.90;8.78) 4.78 (1.52;16.5) 3.92 (1.11;17.2) 2.85 (0.92;9.48) 2.67 (0.74;11.86) Time since diagnosis of metastases§§ 1.06 (1.01;1.11) 0.98 (0.94;1.01) 1.01 (0.99;1.04) 0.98 (0.95;1.01) 1.02 (0.99;1.05) 1.01 (0.98;1.03) 1.02 (0.99;1.07) CEA level before treatment 1.00 (0.99-1.00) 1.00 (95%CI 0.99-1.00) 1.00 (95%CI 0.99-1.00) 1.00 (95%CI 0.99-1.00) 1.00 (0.99-1.00) 1.00 (0.99-1.01) 1.00 (0.99-1.01) Primary tumor location 3.88 (1.00-25.75) 0.88 (0.26-2.63) 0.98 (0.35-2.63) 1.72 (0.65-4.59) 2.96 (0.98-11.11) 0.94 (0.36-2.49) 3.88 (1.00-25.76) Tumor load† – 25%-50% 1.63 (0.50-6.35) 0.56 (0.14-1.79) 1.17 (0.42-3.16) 0.58 (0.20-1.59) 0.94 (0.34-2.72) 1.04 (0.39-2.74) 1.11 (0.36-3.90), 0.7 Tumor load - >50% 0.73 (0.20-3.10) 1.24 (0.30-4.49) 1.67 (0.47-5.76) 1.64 (0.48-5.76) 0.55 (0.16-1.95) 1.66 (0.49-6.12) 0.66 (0.18-2.77) Thistableshowstheassociations(oddsratioand95%CI)betweenbaselinecharacteristicsandmodesofprogressionasdescribedbyRECISTat3monthspost-treatment. * previous treatment with 1st versus 2nd line chemotherapy ** Yttrium-90 resin (reference) versus yttrium-90 glass and holmium-166 *** WHO performance status 0 versus 1, 2 § KRAS mutation versus KRAS wild type §§ Right-sided primary tumors versus left-sided primary tumors † <25% liver involvement versus 25%-50% and >50% liver involvement Abbreviations: GIHM = growth of intrahepatic metastases. GEHM = growth of extrahepatic metastases. NIHM = new intrahepatic metastases. NEHM = new extrahepatic metastases. GM = growth of metastases (GEHM + GIHM). NM = new metastases (NEHM + NIHM). NA = not applicable. RE = radioembolization. OR = odds ratio. PD = progressive disease. 95% CI = 95% confidence interval. 5